Philadelphia University + Thomas Jefferson University

Brody, Jonathan

< Back

Profile

jrb006

Jonathan Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Curtis 611A
Philadelphia, PA 19107

(215) 955-2693
(215) fax

Medical School

PhD, Johns Hopkins University School of Medicine
Post-doctoral Oncology Fellowship with Scott Kern, MD, Johns Hopkins University
PanCAN-AACR Career Development Award, 2010

Research and Clinical Interests

During his over ten years of training at Johns Hopkins University, Dr. Brody began exploring drug-target interactions. Utilizing diverse molecular biology techniques that include DNA sequencing, gene knockout and silencing assays, and development of a drug metabolism assay, Dr. Brody has published extensively on aspects of chemotherapeutics, namely gemcitabine, 5-fluorouracil and platinum-based agents. Part of this work includes his special interest in targeting cancer cells with defects in the BRCA2/Fanconi Anemia pathway. His work also includes the advancement in the basic DNA detection technique of DNA electrophoresis, by discovering new and better alternatives to tris-based buffers, such as lithium-based buffers, that can separate DNA at a fraction of the time compared to conventionally used conductive media. In regards to mRNA stability, Dr. Brody aided in cloning members of the pp32 gene family over a decade ago. Members of this family, pp32 and APRIL, have been shown previously to be ligands and functionally interact with the RNA binding protein, HuR. Currently, Dr. Brody's work focuses on how HuR biology is involved in pancreatic tumorigenesis as well as cancer cell survival. His laboratory is also interested in how HuR expression levels and protein subcellular localization affects treatment of pancreatic cancer. Recently, the group published work showing that HuR subcellular localization is a valuable predictive marker for the standard of care (i.e., gemcitabine) for this disease. His laboratory's work is now primarily focused on HuR biology as it relates to the clinical management of cancer, including identifying clinically relevant HuR targets. Besides his laboratory work, Dr. Brody was recently named Director of Surgical Research and is Co-director of the Jefferson Pancreas, Biliary and Related Cancer Center at Thomas Jefferson University. He recently won the national PanCAN-AACR Career Development award and an American Cancer Society, Research Scholar Grant for his work on HuR's role in pancreatic cancer.

Publications

Most Recent Peer-Reviewed Publications

  1. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors
  2. Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells
  3. CRISPR knockout of the HuR gene causes a xenograft lethal phenotype
  4. Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas
  5. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
  6. Therapeutic implications of molecular subtyping for pancreatic cancer
  7. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer
  8. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment
  9. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative
  10. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial
  11. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner
  12. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR
  13. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells
  14. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy
  15. Delivery of Therapeutics Targeting the mRNA Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth
  16. The landscape of pancreatic cancer therapeutic resistance mechanisms
  17. Personalized therapy for Pancreatic Cancer: Do we need better targets, arrows, or both?
  18. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
  19. HuR contributes to TRAIL resistance by restricting death receptor 4 expression in pancreatic cancer cells
  20. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis